News
5 Things You Probably Didn't Know About Pfizer Inc.
Many people can name one of Pfizer's (NYSE: PFE) products. From over-the-counter products such as Advil and Robitussin to powerful prescription drugs such as Eliquis and Ibrance, Pfizer makes some of
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
$45 billion for five experimental drugs.That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the net present
Better Buy: AbbVie Inc. vs. Johnson & Johnson
U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls
Here's How to Find the Best Dividend Stocks
Finding great income stocks would be easy if the only metric that mattered was yield. If that was true, then an investor would simply screen for the highest-yielding stocks they could find and buy
Rule Breaker Mailbag: Is Corporate Leadership Really as Important as the Fool Says?
In this segment from Rule Breaker Investing, Motley Fool co-founder David Gardner attempts to answer a Foolish investor who is skeptical that the leadership ability and style of CEOs and executive
5 Off-the-Radar Numbers to Take Note of in Johnson & Johnson's Second-Quarter Report
It's officially earnings season, which can only mean one thing: Johnson & Johnson (NYSE: JNJ) is kicking things off for big pharmaceutical companies.On Tuesday morning, July 18, Johnson & Johnson
3 Stocks to Supplement Your Social Security Income
Most American retirees depend on Social Security for at least half their retirement income. While it has been a reliable source of income for generations, Social Security's future looks a lot shakier
Does Puma Biotechnology's Approval Make It Worth More?
Puma Biotechnology's (NASDAQ: PBYI) roller-coaster ride to approval is finally over. After fits and starts in clinical trials, the FDA gave the company's breast cancer drug, Nerlynx, a green light
UnitedHealth Group's Sales Surge Above $50 Billion, Despite Exiting Obamacare
UnitedHealth Group's (NYSE: UNH) decision to stop selling Obamacare plans this year hasn't dented its momentum. The nation's biggest health insurer reported sales of $50 billion in the second quarter
UnitedHealth Sees a Healthier Future
Healthcare is front and center in Washington once more, and lawmakers have made little progress toward making anticipated changes on the insurance front. In the absence of more reform efforts, health
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic
Johnson & Johnson (NYSE: JNJ) owes much of its recent success to the strength of its pharmaceutical division. Even though the company also has extensive exposure to other parts of the healthcare
5 Big Pharma Stocks With the Best Drug Pipelines
Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.Market research firm
3 Healthcare Stocks for Ambitious Investors
While we Fools generally prefer to invest in companies that have battle-tested business models, we do recognize that it can be a smart idea to swing for the fences every now and then.So which stocks
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results
It's that time again, folks: Earnings season is kicking into full swing. And with that comes healthcare conglomerate Johnson & Johnson's (NYSE: JNJ) quarterly report, which often sets the tone for the
3 Small Biotech Stocks Being Run by Proven Winners
Great leaders are important in any industry, but perhaps they're even more valuable in biotech, where any number of clinical-stage and regulatory obstacles can derail drug research and send share
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Pfizer (NYSE: PFE) stands at the top of the mountain when it comes to prescription drug sales. Last year, the big pharma company made $45.9 billion from prescription drugs, well ahead of runners-up
Roundtable: 1 Stock I'm Never Selling
Stocks that are worth buying and holding for exceptionally long periods of time are far less common than most investors may think. Changes in underlying market conditions, after all, can knock even
What Managed Care Organizations Are, and How Investors Can Profit From Them
Most Americans get their healthcare through a managed care organization, but nearly no one truly knows the ins and outs of the health insurance program they have. Managed care organizations are plans
Johnson & Johnson Looks for Second-Quarter Strength to Keep Upward Momentum
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) has been immensely successful over the years, and it has also done well for shareholders recently. With a nearly 15% rise so far in 2017, Johnson
Pfizer: International schwache Umsätze belasten!
Lieber Leser,
Pfizer hat in der vergangenen Woche den Quartalsbericht für das erste Quartal 2017 vorgelegt. Das Unternehmen hat die Schätzungen der Analysten bei den Umsätzen verfehlt, jedoch beim....
UnitedHealth Group: Starkes Geschäftsjahr!
Liebe Leser,
UHG hat ein starkes Geschäftsjahr hinter sich gelassen. Trotz einiger Schwierigkeiten mit der Abwicklung der teuren „Obamacare-Verträge“ konnte der US-Gesundheitskonzern....
Merck & Co. ÜBERTRIFFT Erwartungen!
Liebe Leser,
Merck übertraf mit seinen Zahlen für die ersten 9 Monate die Erwartungen des Marktes. Bei einem Umsatz leicht über Vorjahresniveau stieg der Gewinn um gut 30%. Der Umsatz mit....
Johnson & Johnson: Überzeugende Ergebnisse!
Liebe Leser,
J&J hat einmal mehr überzeugende Ergebnisse präsentiert. In den ersten 9 Monaten stiegen der Umsatz um 2,9% und der Gewinn um 4,4%. Wachstumstreiber war die PharmaSparte mit....
Pfizer – Expansion des irischen Werks wird aufgehoben!
Lieber Leser,
der Pharma-Riese Pfizer hat seine Pläne verworfen, 400 Millionen Euro in die Expansion der irischen Produktionsstätte in Dublin zu investieren. 350 geplante Langzeitarbeitsplätze....
Pfizer: How a 15% Decline is a Gift to Income Investors
Pfizer (PFE) stock has declined 15% from its 52-week closing high, of $37.31 per share. The positive aspect of this is that it gives income investors a better buying opportunity.
